Cargando…
A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment
ABSTRACTS: BACKGROUND: Clomiphene citrate (CC) is most commonly used as a first-line treatment of infertility. However, a disturbance of endometrial growth by the adverse effects of the CC has been recognized. Since a thin endometrium is recognized as a critical factor of implantation failure, preve...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880974/ https://www.ncbi.nlm.nih.gov/pubmed/24369731 http://dx.doi.org/10.1186/1757-2215-6-94 |
_version_ | 1782298135684448256 |
---|---|
author | Takasaki, Akihisa Tamura, Hiroshi Taketani, Toshiaki Shimamura, Katsunori Morioka, Hitoshi Sugino, Norihiro |
author_facet | Takasaki, Akihisa Tamura, Hiroshi Taketani, Toshiaki Shimamura, Katsunori Morioka, Hitoshi Sugino, Norihiro |
author_sort | Takasaki, Akihisa |
collection | PubMed |
description | ABSTRACTS: BACKGROUND: Clomiphene citrate (CC) is most commonly used as a first-line treatment of infertility. However, a disturbance of endometrial growth by the adverse effects of the CC has been recognized. Since a thin endometrium is recognized as a critical factor of implantation failure, preventing CC-induced thinning of the endometrium is important. This study was undertaken to investigate whether the modified CC treatments are useful to prevent a thin endometrium in patients undergoing CC treatments. METHODS: This study is a prospective, randomized controlled study. The study was performed at the Saiseikai Shimonoseki General Hospital during a 4-month period (May 2012 to September 2012). Sixty-six infertile women who had a thin endometrium (< 8 mm) during the standard CC treatment (50 mg/day on days 5–9 of the menstrual cycle) were enrolled. The patients were randomly divided into three groups: 22 patients were given 25 mg/day CC on days 5–9 (half-dose group), 22 patients were given 50 mg/day CC on days 1–5 (early administration group) and 22 patients received a standard CC treatment again (control group). Endometrial thickness at the induction of ovulation was assessed by ultrasonography. The primary endpoint of this study was an endometrial thickness. RESULTS: Half dose administration and early administration improved the endometrial thickness (≥ 8 mm) in 14 patients (70%) and in 19 patients (90%) respectively, while only 3 patients (15%) improved in endometrial thickness in the control group. The mean endometrial thickness was also significantly higher in the half dose group (8.6 ± 1.5 mm) and early administration group (9.4 ± 1.5 mm) compared to the control group (6.7 ± 1.8 mm). No side effect was observed in this study. CONCLUSIONS: The modified treatment with a half-dose or early administration of CC significantly increased endometrial thickness in patients with a history of thin endometrium caused by the standard CC regimen. The modified CC treatments in this study can be beneficial for patients with a thin endometrium as a result of standard CC treatment. TRIAL REGISTRATION: Clinical Trial Registration Number: UMIN000007959. |
format | Online Article Text |
id | pubmed-3880974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38809742014-01-07 A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment Takasaki, Akihisa Tamura, Hiroshi Taketani, Toshiaki Shimamura, Katsunori Morioka, Hitoshi Sugino, Norihiro J Ovarian Res Research ABSTRACTS: BACKGROUND: Clomiphene citrate (CC) is most commonly used as a first-line treatment of infertility. However, a disturbance of endometrial growth by the adverse effects of the CC has been recognized. Since a thin endometrium is recognized as a critical factor of implantation failure, preventing CC-induced thinning of the endometrium is important. This study was undertaken to investigate whether the modified CC treatments are useful to prevent a thin endometrium in patients undergoing CC treatments. METHODS: This study is a prospective, randomized controlled study. The study was performed at the Saiseikai Shimonoseki General Hospital during a 4-month period (May 2012 to September 2012). Sixty-six infertile women who had a thin endometrium (< 8 mm) during the standard CC treatment (50 mg/day on days 5–9 of the menstrual cycle) were enrolled. The patients were randomly divided into three groups: 22 patients were given 25 mg/day CC on days 5–9 (half-dose group), 22 patients were given 50 mg/day CC on days 1–5 (early administration group) and 22 patients received a standard CC treatment again (control group). Endometrial thickness at the induction of ovulation was assessed by ultrasonography. The primary endpoint of this study was an endometrial thickness. RESULTS: Half dose administration and early administration improved the endometrial thickness (≥ 8 mm) in 14 patients (70%) and in 19 patients (90%) respectively, while only 3 patients (15%) improved in endometrial thickness in the control group. The mean endometrial thickness was also significantly higher in the half dose group (8.6 ± 1.5 mm) and early administration group (9.4 ± 1.5 mm) compared to the control group (6.7 ± 1.8 mm). No side effect was observed in this study. CONCLUSIONS: The modified treatment with a half-dose or early administration of CC significantly increased endometrial thickness in patients with a history of thin endometrium caused by the standard CC regimen. The modified CC treatments in this study can be beneficial for patients with a thin endometrium as a result of standard CC treatment. TRIAL REGISTRATION: Clinical Trial Registration Number: UMIN000007959. BioMed Central 2013-12-27 /pmc/articles/PMC3880974/ /pubmed/24369731 http://dx.doi.org/10.1186/1757-2215-6-94 Text en Copyright © 2013 Takasaki et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Takasaki, Akihisa Tamura, Hiroshi Taketani, Toshiaki Shimamura, Katsunori Morioka, Hitoshi Sugino, Norihiro A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment |
title | A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment |
title_full | A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment |
title_fullStr | A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment |
title_full_unstemmed | A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment |
title_short | A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment |
title_sort | pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880974/ https://www.ncbi.nlm.nih.gov/pubmed/24369731 http://dx.doi.org/10.1186/1757-2215-6-94 |
work_keys_str_mv | AT takasakiakihisa apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT tamurahiroshi apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT taketanitoshiaki apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT shimamurakatsunori apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT moriokahitoshi apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT suginonorihiro apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT takasakiakihisa pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT tamurahiroshi pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT taketanitoshiaki pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT shimamurakatsunori pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT moriokahitoshi pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment AT suginonorihiro pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment |